Therapeutic Effects of Human Mesenchymal Stem Cells in a Mouse Model of Cerebellar Ataxia with Neuroinflammation.
Youngpyo NamDongyeong YoonJungwan HongMin Sung KimTae-Yong LeeKyung Suk KimHo-Won LeeKyoungho SukSang Ryong KimPublished in: Journal of clinical medicine (2020)
Cerebellar ataxias (CAs) are neurological diseases characterized by loss of muscle coordination that is a result of damage and inflammation to the cerebellum. Despite considerable efforts in basic and clinical research, most CAs are currently incurable. In this study, we evaluated the therapeutic potential of human mesenchymal stem cells (hMSCs) against CAs associated with neuroinflammation. We observed that hMSC treatment significantly inhibited the symptoms of ataxia in lipopolysaccharide (LPS)-induced inflammatory CA (ICA) mice, which were recently reported as a potential animal model of ICA, through the anti-inflammatory effect of hMSC-derived TNFα-stimulated gene-6 (TSG-6), the protection of Purkinje cells by inhibition of apoptosis, and the modulatory effect for microglial M2 polarization. Thus, our results suggest that hMSC treatment may be an effective therapeutic approach for preventing or improving ataxia symptoms.
Keyphrases
- lps induced
- mesenchymal stem cells
- inflammatory response
- oxidative stress
- crispr cas
- endothelial cells
- genome editing
- lipopolysaccharide induced
- cell cycle arrest
- induced apoptosis
- mouse model
- early onset
- traumatic brain injury
- rheumatoid arthritis
- anti inflammatory
- bone marrow
- umbilical cord
- endoplasmic reticulum stress
- pluripotent stem cells
- cell death
- skeletal muscle
- induced pluripotent stem cells
- genome wide
- metabolic syndrome
- stem cells
- adipose tissue
- brain injury
- dna methylation
- cerebral ischemia
- combination therapy
- spinal cord
- physical activity
- cell therapy
- depressive symptoms
- human health
- smoking cessation